2018
Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α)
Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J. Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α). Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 115: 8340-8345. PMID: 30061385, PMCID: PMC6099872, DOI: 10.1073/pnas.1807881115.Peer-Reviewed Original ResearchConceptsLeukocyte tyrosine kinaseN-terminal variable regionDeletion mutantsVariable regionsDisulfide bridgesDetailed biochemical characterizationIntramolecular disulfide bridgesNIH 3T3 cellsSimilar tyrosine phosphorylationAnaplastic lymphoma kinaseReceptor-receptor interactionsMAP kinase responseTyrosine phosphorylationBiochemical characterizationTyrosine kinaseReceptor tyrosineNeuronal differentiationL6 cellsPhysiological roleMode of actionKinase responseCultured cellsPC12 cells
2016
Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition
Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I. Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e4784-e4793. PMID: 27482095, PMCID: PMC4995958, DOI: 10.1073/pnas.1610179113.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsCombination of TKIsAnti-Kit antibodiesKIT mutantsPrecision medicine treatmentAntibody treatmentMedicine treatmentLow dosePrecision medicine effortsToxin conjugatesKIT inhibitorsActivating mutationsDistinct cellular propertiesReceptor tyrosine kinasesKinase inhibitorsCell inhibitionCancer cellsGenomic sequencing analysisCancer cell inhibitionMedicine effortsCancerTreatmentTyrosine kinaseSequencing analysisInhibitors
2015
Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J. Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions. Proceedings Of The National Academy Of Sciences Of The United States Of America 2015, 112: 15862-15867. PMID: 26630010, PMCID: PMC4702955, DOI: 10.1073/pnas.1520099112.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnaplastic Lymphoma KinaseAnimalsCell LineCell Line, TumorCell ProliferationCytokinesDoxycyclineEnzyme ActivationHEK293 CellsHeparinHumansImmunoblottingLigandsMiceMolecular Sequence DataNIH 3T3 CellsProtein BindingReceptor Protein-Tyrosine KinasesSequence Homology, Amino AcidConceptsLeukocyte tyrosine kinaseReceptor tyrosine kinasesTyrosine kinaseIL-3-independent growthCritical cellular functionsBa/F3 cellsCell surface receptorsAnaplastic lymphoma kinaseLigand-receptor interactionsCellular functionsLigand bindingF3 cellsReceptor tyrosineProtein ligandsNIH/3T3 cellsKinaseSurface receptorsIndependent growthSubnanomolar potencyCellsDisease statesHigh affinityLymphoma kinaseFAM150ANovel cytokine
2014
The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer
Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J. The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell 2014, 57: 191-201. PMID: 25544564, PMCID: PMC4764128, DOI: 10.1016/j.molcel.2014.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBaculoviridaeBinding SitesCrystallography, X-RayEnzyme ActivationHumansLigandsMiceModels, MolecularMutationNeoplasmsNIH 3T3 CellsProtein BindingProtein FoldingProtein Interaction Domains and MotifsProtein MultimerizationProtein Structure, SecondaryProto-Oncogene Proteins c-kitRecombinant ProteinsSf9 CellsSpodopteraConceptsOncogenic KIT mutationsKIT mutationsGastrointestinal stromal tumorsAcute myeloid leukemiaKIT tyrosine kinase activitySomatic oncogenic mutationsInterstitial pacemaker cellsLigand-dependent stimulationReceptor tyrosine kinase KITStromal tumorsTyrosine kinase KITMyeloid leukemiaReceptor activationPacemaker cellsTyrosine kinase activityCancerKinase KITOncogenic mutationsHematopoietic cellsGerm cellsOncogenic activationActivationCellsReceptor moleculesMutations
2006
Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis
Eswarakumar VP, Özcan F, Lew ED, Bae JH, Tomé F, Booth CJ, Adams DJ, Lax I, Schlessinger J. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 18603-18608. PMID: 17132737, PMCID: PMC1693709, DOI: 10.1073/pnas.0609157103.Peer-Reviewed Original ResearchConceptsFGF receptorsDocking protein FRS2alphaCommon craniofacial abnormalitySelective uncouplingPremature fusionSkull developmentFunction mutationsDominant mutationsNormal skull developmentMurine model systemMutationsSevere bone disordersModel systemFGFR2cCraniofacial abnormalitiesCalvaria organ culturesPathwayOrgan cultureFRS2alphaSkull vaultMutantsPharmacological approachesFusionFGFRUncoupling